Publications by authors named "A Sexton-Oates"
Biological mechanisms related to cancer development can leave distinct molecular fingerprints in tumours. By leveraging multi-omics and epidemiological information, we can unveil relationships between carcinogenesis processes that would otherwise remain hidden. Our integrative analysis of DNA methylome, transcriptome, and somatic mutation profiles of kidney tumours linked ageing, epithelial-mesenchymal transition (EMT), and xenobiotic metabolism to kidney carcinogenesis.
View Article and Find Full Text PDFIntroduction: Multi-omic studies have identified three molecular separated pulmonary carcinoid (PC) subgroups (A1, A2, B) with distinctive mRNA expression profiles (e.g., orthopedia homeobox protein [OTP], achaete-scute homolog [ASCL1], and hepatocyte nuclear factor 1 homeobox A [HNF1A]).
View Article and Find Full Text PDFArticle Synopsis
- The study aims to understand how specific molecular changes, particularly the expression of a certain gene, influence the clinical outcomes of patients with pulmonary carcinoids, which can range from slow-growing to deadly tumors.
- Researchers analyzed RNA sequencing data from two cohorts of pulmonary carcinoid patients (totaling 193) to determine the prognostic value of this gene expression and its relationship with telomerase activity, which is linked to tumor aggressiveness.
- Results showed that high expression of the gene correlates with worse survival rates and is an independent predictor of poor clinical outcomes, suggesting that it could be a key factor in assessing the severity of pulmonary carcinoids.
Background And Purpose: CNS embryonal tumor with amplification (ET, PLAGL) is a newly identified, highly malignant pediatric tumor. Systematic MRI descriptions of ET, PLAGL are currently lacking.
Materials And Methods: MRI data from 19 treatment-naïve patients with confirmed ET, PLAGL were analyzed.
Background: Six thoracic pathologists reviewed 259 lung neuroendocrine tumours (LNETs) from the lungNENomics project, with 171 of them having associated survival data. This cohort presents a unique opportunity to assess the strengths and limitations of current World Health Organization (WHO) classification criteria and to evaluate the utility of emerging markers.
Patients And Methods: Patients were diagnosed based on the 2021 WHO criteria, with atypical carcinoids (ACs) defined by the presence of focal necrosis and/or 2-10 mitoses per 2 mm.